Drug prescription in mild cognitive impairment: the physicians' perspective in Italy

Today there are no data on the type of drugs prescribed to MCI patients nor the prevalence of their prescription. The aim of this study was to describe which drugs were prescribed in 2004 for cognitive and non cognitive disturbances of patients with MCI in a sizable group of Italian expert centers for the diagnosis and treatment of Alzheimer's disease.

[1]  H. Refsum,et al.  A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia , 1992, Acta psychiatrica Scandinavica.

[2]  M. Tuszynski,et al.  A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease , 1996, Neurology.

[3]  K. Marder,et al.  Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. , 1992, Archives of neurology.

[4]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[5]  W. Herrmann,et al.  Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. , 1990, International journal of clinical pharmacology research.

[6]  A. Burns,et al.  Alarming arbitrariness in EU prescription and reimbursement criteria for anti‐dementia drugs , 2006, International journal of geriatric psychiatry.

[7]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[8]  S. Salloway,et al.  Efficacy of donepezil in mild cognitive impairment , 2004, Neurology.

[9]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[10]  M. Doyle,et al.  Survival ofCampylobacter jejuni in the presence of bisulfite and different atmospheres , 1983, European Journal of Clinical Microbiology.

[11]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[12]  C. Lyketsos,et al.  Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. , 2000, The American journal of psychiatry.

[13]  G. Livingston,et al.  Acetyl‐L‐Carnitine in dementia , 1991 .

[14]  William E. Klunk,et al.  Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease , 1995, Neurobiology of Aging.

[15]  A. Lajtha,et al.  Effect of acetyl-l-carnitine on extracellular amino acid levels in vivo in rat brain regions , 1993, Neurochemical Research.

[16]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[17]  Alessandro Padovani,et al.  The Predementia Diagnosis of Alzheimer Disease , 2004, Alzheimer disease and associated disorders.

[18]  M. Maggini,et al.  A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease , 2005, European Journal of Clinical Pharmacology.

[19]  M. Alberoni,et al.  Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease , 1991, Neurology.

[20]  D. Cucinotta,et al.  Acetyl-L-carnitine in the treatment of mildly demented elderly patients. , 1990, International journal of clinical pharmacology research.

[21]  A. N. Exton-smith,et al.  Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. , 1990, Current medical research and opinion.

[22]  L. Thal,et al.  A 1-year controlled trial of acetyl-l-carnitine in early-onset AD , 2000, Neurology.

[23]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[24]  C. Lyketsos,et al.  Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. , 2002, JAMA.

[25]  D. Cucinotta,et al.  Multicenter clinical placebo‐controlled study with acetyl‐l‐carnitine (LAC) in the treatment of mildly demented elderly patients , 1988 .

[26]  L. Thal,et al.  Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease , 2003, International clinical psychopharmacology.